Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland. The American biotech firm Novavax had applied for approval on February 14 through Swiss partner Future Health Pharma.
Unlike other Covid-19 vaccine approved in Switzerland – the mRNA vaccines from Pfizer/BioNTech and Moderna and the viral vector vaccine from Johnson & Johnson – Nuvaxovid is a protein-based vaccine. According to Swissmedic, it contains a non-infectious component from the surface of the SaRS-CoV-2 virus which triggers a protective immune response when the body’s immune cells come into contact with it. The vaccine contains an adjuvant to strengthen the immune response.
The vaccine must be administered in two doses three weeks apart. The level of protection offered by Nuvaxovid seven days after the second dose is 90%. It can be stored in a refrigerator for up to nine months.
“We are proud that Switzerland is part of the growing list of countries approving Nuvaxovid and that people in Switzerland will have a protein-based Covid-19 vaccine option,” said Novavax CEO Stanley C. Erck.
Swissmedic’s decision was based on the totality of preclinical, manufacturing and clinical trial data submitted for review. This includes two pivotal phase III clinical trials: PREVENT-19, which enrolled approximately 30,000 participants aged 18 and older in the US and Mexico and was published in the New England Journal of Medicine.
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Swiss fencers apologise for diplomatic scandal with Israel
This content was published on
Two days after causing a diplomatic scandal at the U23 European Championships in Tallinn, the Swiss fencers responsible have published a jointly signed apology on Instagram.
Air in climbing gyms more polluted than on streets
This content was published on
The concentration of potentially harmful chemicals in climbing gyms is sometimes higher than on busy roads, say researchers from Switzerland and Austria.
This content was published on
Swiss International Air Lines (SWISS) achieved slightly higher sales at the start of the year. However, profits fell sharply, partly due to the late Easter.
Switzerland’s first padel court on water built in Arosa
This content was published on
Switzerland's first padel tennis court on water will open on the Obersee in Arosa, canton Graubünden, for the 2025 summer season.
This content was published on
Wine consumption in Switzerland fell by almost 8% in 2024 compared to the previous year. Swiss wines are particularly affected by the decline.
Jackie Chan to be honoured for life’s work at Locarno Film Festival
This content was published on
Martial artist Jackie Chan will receive an Honorary Leopard, a lifetime achievement award, from the Locarno Film Festival in southern Switzerland in August.
Novartis raises forecast again after strong Q1 results
This content was published on
Swiss pharmaceutical giant Novartis has continued the strong pace of growth of recent quarters in the first three months of 2025.
Swiss canton holds first general meeting on winegrowing
This content was published on
More than 250 professionals attended the first general meeting of the Valais wine industry on Monday in Conthey, western Switzerland.
Greater transparency called for in Swiss use of medical imaging
This content was published on
More and more scans, ultrasounds and MRIs: doctors are increasingly prescribing medical imaging tests, particularly in the French-speaking cantons.
Renewal of war in Gaza has ‘unleashed a new hell’, says Red Cross
This content was published on
The resumption of the war in Gaza has unleashed a new hell in the Palestinian territory, the director of the Geneva-based ICRC has warned.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.